iGene®Non-Invasive Prenatal Test (NIPT)
iGene® Non-Invasive Prenatal Test (NIPT) that analyses cell-free fetal DNA (cffDNA) present in maternal blood. This DNA comes from the placenta and circulates freely in the maternal bloodstream.
iGene® NIPT screens for Trisomy 21 (Down Syndrome), Trisomy 18 (Edward Syndrome), Trisomy 13 (Patau Syndrome), Sex Chromosome Aneuploidies and selected Deletions1.
What iGene® NIPT covers
iGene® NIPT can detect Trisomy 21, 18, 13, Sex Chromosome Aneuploidies and selected Deletion Syndromes. iGene® NIPT can be performed on expectant mothers who may be considering, or have been offered, prenatal testing for fetal trisomy2.
Trisomy Aneuploidies 1
- Trisomy 21 (Down Syndrome)
- Trisomy 18 (Edwards Syndrome)
- Trisomy 13 (Patau Syndrome)
Sex Chromosome Aneuploidies 3
-
Trisomy X (Triple X Syndrome)
-
Monosomy X (Turner Syndrome)
-
XXY (Klinefelter Syndrome)
-
XYY (Jacobs Syndrome)
Deletion/Duplication Syndromes *
- 2q11.2 Deletion Syndrome (DiGeorge Syndrome)
- 5p-Deletion Syndrome (Cri du Chat Syndrome)
- 1p36 Deletion Syndrome
- 16p12.2 Deletion Syndrome
- 2q33.1 Microdeletion Syndrome
- 11q23 Microdeletion Syndrome (Jacobsen Syndrome)
- 1q32.2 Microdeletion Syndrome (Van der Woude Syndrome)
- 15q11.2 Microdeletion Syndrome (Prader-Willi/Angelman Syndrome)
Additional Trisomies *
-
Trisomy 9
-
Trisomy 16
-
Trisomy 22
Fetal Sex *
-
Information on fetal sex will be reported if requested.
iGene® NIPT is powered by BGI Technology.
Medical treatment has to be individualised and can only be rendered after adequate assessment of your condition through appropriate clinical examination, and after discussion with your doctor. You should not rely on the information provided herein. Please note that the contents of this page are provided on the understanding that no surgical or medical advice or recommendation is being rendered.
Sources:
1. Zhang et al.,Ultrasound Obstet. & Gynecol 2015
2. Liu H, et al., PLoS One 2016.
3. Jiang F, et al. BMC Medical Genomics, 2012, 5:57.
* Based on in-silico data.
Do contact our partners to find out more by
clicking on them below.
Preeclampsia Screening (PlGF)
During pregnancy, the placenta plays a central role by supplying nutrients and oxygen to the baby, and any issues with its development and function can contribute to preeclampsia. Abnormalities in blood vessels can lead to restricted blood flow to the placenta, triggering the onset of preeclampsia.
Developing preterm preeclampsia, a condition that can occur before 37th week of pregnancy, poses significant risks to both the pregnant mother and the baby.
Common signs and symptoms of preeclampsia
Viability Ultrasound
Viability Ultrasound is a medical imaging test used to assess the health and development of a fetus during pregnancy. It measures the baby’s heart rate, blood flow, and movement to determine their overall viability and potential health risks.
Blood Test
A first trimester blood test, also known as a maternal serum screening test, performed during early pregnancy that measures levels of certain proteins and biomarkers, and to check for full blood count, blood groups and sexually transmitted diseases.
Dating Ultrasound
Dating Ultrasound, also known as early ultrasound or dating scan, is a prenatal test that uses sound waves to create images of the growing fetus during the early stages of pregnancy. It is typically performed between 6 and 12 weeks of gestation to estimate the age of the fetus, confirm pregnancy, and detect any potential issues.
The ultrasound can also provide information on the fetus’s sex, heart rate, and overall development.
Chorionic Villus Sampling (CVS)
Chorionic Villus Sampling (CVS) is a prenatal diagnostic test that involves removing a small sample of cells from the placenta to check for genetic disorders or other conditions. It is typically performed between 10 and 12 weeks of pregnancy and can provide information about the baby’s genetic health, including chromosomal abnormalities, and inherited diseases.
One-Stop Clinic for Assessment of Risk for foetal anomalies (OSCAR)
OSCAR involves an ultrasound scan and blood tests (BHCG and PAPP-A) performed between 11 to 13 weeks +6 days to assess the risks of certain genetic disorders or birth defects. The ultrasound scan is used to assess the thickness of the skin in the neck of the foetus. These test results may help couples decide if they want to proceed with confirmatory invasive test.
